Mutations in the oncogene BRAF(V600E) are found in~10% of colorectal cancers (CRCs) and are associated with poor prognosis. However, BRAF(V600E) has a limited response to the smallmolecule drug, vemurafenib, a BRAF inhibitor, and BRAF inhibition is thought to cause a feedback activation of EGFR signaling that supports continued proliferation. In this study, we explored the effect of combined use of dabrafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, on BRAF(V600E)-mutant CRC stem cells and its possible mechanisms. Through cell viability analysis, flow cytometry, sphere forming, and western blot analysis, we found that the dabrafenib can synergize with cetuximab to reduce cell viability, induce enhanced apoptotic rates and cell cycle arrest in BRAF(V600E)-mutant HT-29 cells and inhibits stem cell capacities. Further, western blot analysis revealed that PTEN/Src/c-Myc pathway is possibly involved in the synergism between dabrafenib and cetuximab. Overall, our study shows that the combination of dabrafenib and cetuximab results in increased antitumor activity and decreased stem cell capacities in BRAF (V600E)-mutant CRC cells.
Introduction
The serine/threonine-protein kinase BRAF is a key component of the RAS-RAF signaling pathway, which regulates cell division through interactions with extracellular growth factors and hormones [1] [2] [3] . Somatic mutations in the BRAF gene are associated with various cancers, including non-Hodgkin lymphoma, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, adenocarcinoma of the lung and colorectal cancer (CRC) [4] [5] [6] [7] [8] [9] [10] . BRAF harbors mutations in~9.6% of CRC patients, with a T1799A substitution being the most frequent and resulting in the replacement of valine 600 by glutamic acid (V600E) [11, 12] . CRC patients with the BRAF (V600E) mutation are found to have a significantly shorter overall survival [13] .
For metastatic colorectal cancer (mCRC) patients, targeted therapies including anti-angiogenesis (bevacizumab) and anti-EGFR (cetuximab) have significantly improved the progression-free survival (PFS) and overall survival (OS) time [14] . Cetuximab plus irinotecan has been approved for mCRC patients with RAS-wild type tumors [15] . However, due to intrinsic or acquired drug resistance, their efficacy is limited. BRAF mutation has been one of the reasons that contribute to the resistance of cetuximab. The V600E mutation occurs in the regions of BRAF that encodes the kinase domain. It leads to the constitutive activation of BRAF and consequent disruption of the downstream regulation by MEK and extracellular signalregulated kinases (ERK), leading to abnormal cell proliferation [16] . However, CRC patients with BRAF(V600E) mutation have only a limited response to the small-molecule drug vemurafenib [14] . Recent studies have indicated that BRAF inhibition causes a rapid feedback activation of EGFR signaling which leads to continued proliferation in the presence of BRAF inhibition [17, 18] .
Clinical studies have shown that higher responses were observed with vemurafenib and cetuximab, an EGFR inhibitor, compared with vemurafenib monotherapy in patients with BRAF valine 600 mutations CRC [19] . The addition of vemurafenib to capecitabine and/or bevacizumab, irinotecan, and erlotinib has also resulted in increased antitumor activity and improved survival in xenograft models [14] . Dabrafenib is a specific inhibitor of BRAF that disrupts the RAF/MEK pathway and have been approved by Food and Drug Administration (FDA) for advanced melanoma patients with positive BRAF(V600E) mutation [20] . However, to our knowledge, the combined use of dabrafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, has not been studied on CRC stem cells. In this study, we assessed the effects of dabrafenib and cetuximab on cell viability, cell cycle, apoptosis, and especially stem cell capacities, and explored its possible underlying mechanism in BRAF(V600E)-mutant HT-29 cells.
Materials and Methods

Cell lines and cell culture
HT-29 (KRAS wt, BRAF-V600E mt), Caco-2 (KRAS wt, BRAF wt), and HCT-116 cells (KRAS mt, BRAF wt) were obtained from Shanghai Cell Bank, Type Culture Collection Committee of Chinese Academy of Science (Shanghai, China). Cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere with 5% CO 2 . For cancer stem cell culture, 800 HT-29 cells/well were enriched by serum-free suspending culture method involving supplements (DMEM-F12 with basic fibroblast growth factor: 10 ng/ml; epidermal growth factor: 20 ng/ml; bovine serum albumin: 0.4%; 50 × B27: 4 ml/l) under ultralow attachment condition for 1 week.
Drugs and reagents
Dabrafenib and AZD0530 were purchased from Selleck Chemical (Houston, USA). Cetuximab (C225; Erbitux) was kindly provided by Merck Company (Darmstadt, Germany). Cetuximab was diluted in phosphate-buffered saline (PBS). Dabrafenib and AZD0530 were diluted in DMSO.
Cell viability assay
Cell viability was measured by using the commercial Cell Counting Kit-8 (CCK-8) assay (Dojindo, Kumamoto, Japan) according to the manufacturer's instructions. Briefly, HT-29 cells were seeded into 96-well cell culture cluster plates (Corning Inc., Corning, USA) with a density of 8000 cells/well in 100-μl culture medium, and grown overnight. The next day, dabrafenib or cetuximab was added to each well at a gradient concentration and cells were incubated for another 48 h. Then, 10 μl of CCK-8 reagents was added to each well and incubated for 2 h at 37°C. Finally, the absorbance was measured with an automated plate reader. The experiments were repeated at least three times.
Flow cytometric analysis
For apoptotic analysis, HT-29 cells were treated with 1 μM dabrafenib, 1 μg/ml cetuximab, or their combination for 48 h. Apoptosis rates were assessed by flow cytometry after staining with Annexin V/propidium iodide (BD Pharmingen, Franklin Lakes, USA). In brief, the cells were harvested, washed twice with cold 1 × PBS and resuspended in 100 μl binding buffer at a density of 1 × 10 5 cells/ml.
Then 5 μl Annexin V and 5 μl propidium iodide were added into cells and incubated for 15 min in the dark. Then flow cytometry was performed and the results were from three independent experiments. After the above indicated treatments, cell cycle was also detected. In brief, the cells were harvested, washed twice in 1 × PBS, fixed with 75% ethanol in PBS at −20°C overnight, and then incubated with 1 mg/ml RNase A for 30 min at 37°C in PBS. The cells were subsequently stained with propidium iodide (50 μg/ml) and analyzed by flow cytometry (Cytomics FC MPL, Beckman Coulter, Pasadena, USA). The results were from three independent experiments.
Migration assay
After indicated treatments as described above, 1 × 10 5 HT-29 cells
were added into the top chamber of the insert well (8 μm pore size; BD Falcon, San Diego, USA) with 200 μl serum-free medium for 72 h. After removal of the non-migrated cells in the top chamber, the remaining cells were fixed with 4% paraformaldehyde, stained with 1% crystal violet and counted under a microscope.
Western blot analysis
Western blot analysis was performed according to the method described previously [21, 22] . Briefly, lysates were obtained from cultured cells using RIPA Buffer with protease inhibitors and phosphatase inhibitors. Proteins were separated by a 10% SDS-PAGE gel and then transferred into polyvinylidene fluoride (PVDF) membranes. After being blocked with 10% skim milk in TBST for 1 h at room temperature, the membranes were probed with the primary antibodies overnight at 4°C, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room temperature. Signals were detected by luminescent image analyzer (ImageQuant LAS4000 mini; GE Healthcare, Bethesda, USA). The following antibodies were used: anti-β-actin (1:2000), anti-PTEN (1:1000), anti-SRC (1:1000), anti-p-SRC(Tyr416) (1:1000), anti-CD44 (1:1000), anti-Oct-4 (1:1000), anti-CBX-7 (1:1000), anti-EZH2 (1:1000), anti-E-cadherin (1:1000), anti-Snail (1:1000), anti-Slug (1:1000), anti-FAK (1:1000), anti-BCL-XL (1:1000), anti-BCL-2 (1:1000), antiSurvivin (1:1000), anti-BAX (1:1000), anti-NF-κB2 p100/p52 (1:1000) and anti-phospho-IKKα(Ser176)/IKKβ(Ser177) (1:1000) antibodies, which were purchased from Cell Signaling Technology (Cambridge, USA). Anti-CDK2 (1:1000) and anti-c-Myc (1:1000) antibodies were from Abcam (Cambridge, USA). Goat anti-rabbit or anti-mouse IgG (1:10000) was from Jackson ImmunoResearch Laboratories (West Grove, USA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 7.0 software. All values were expressed as the mean ± SEM of at least three separate experiments. Two-tail Student's t-test was used for the comparisons of two independent groups.
Results
Dabrafenib reduces the viability of BRAF(V600E)-mutant HT-29 cells by synergizing with cetuximab
To assess the cytotoxic effect of cetuximab and dabrafenib, CRC cells were exposed to gradient concentrations of dabrafenib, cetuximab or their combination for 48 h. The cell viability was then assessed by CCK-8 assay. It was found that a combination of dabrafenib and cetuximab had a significantly increased cytotoxic effect with the lowest cell viability found in BRAF(V600E)-mutant HT-29 cells (Fig. 1A-C) . However, no synergistic effects were observed in Caco-2 (KRAS wt, BRAF wt) and HCT-116 (KRAS mt, BRAF wt) cells. These results indicate that dabrafenib may synergize with cetuximab only in BRAF(V600E)-mutant CRC cells. For BRAF wt CRC cells, such synergism might not exist.
Combination of dabrafenib with cetuximab enhances apoptotic rates and cell cycle arrest in HT-29 cells
The effects of combined use of dabrafenib with cetuximab on apoptosis and cell division were assessed in HT-29 cells harboring BRAF (V600E) mutation. After treatment with 1 μM dabrafenib, 1 μg/ml cetuximab or their combination for 48 h, cells were detected by flow cytometry. Combined therapy displayed increased apoptotic rates when compared with monotherapy ( Fig. 2A) . There was a significantly higher percentage of apoptotic cells (Fig. 2B) following the combined treatment compared with treatment with either agent alone. The distribution of cell cycle was also assessed in the HT-29 cells (Fig. 2C,D) . The percentage of S-phase cells was significantly decreased in combined therapy and in dabrafenib monotherapy compared with the control and cetuximab monotherapy (control, 27.56%; dabrafenib, 7.33%; cetuximab, 24.15%; dabrafenib + cetuximab, 5.80%).
To confirm that combined therapy influences cell division and the rate of apoptosis, the expression levels of cell cycle regulatory proteins (cyclin-dependent kinase 2, CDK2) and apoptotic-associated proteins (BCL-2, BCL-XL, BAX, and Survivin) were evaluated by western blot analysis (Fig. 2E) . Level of CDK2, a catalytic subunit of the cyclindependent kinase complex that is active in the G1 to S-phase of the cell cycle, was decreased in response to dabrafenib and the combined therapy. Levels of the anti-apoptotic-associated proteins BCL-2, BCL-XL, and Survivin were reduced, while the expression of pro-apoptotic protein BAX was up-regulated in the HT-29 cells after treated with dabrafenib, cetuximab or their combination.
Overall, these results support that the combined use of dabrafenib and cetuximab induces enhanced apoptotic rates and cell cycle arrest.
Dabrafenib cooperates with cetuximab to inhibit stem cell and migration capacities in HT-29 cells
Self-renewal activity was assessed by culturing HT-29 cells in a serum-free microsphere for 1 week after 48 h of incubation with either 1 μM dabrafenib, 1 μg/ml cetuximab or their combination. As shown in Fig. 3A ,C, the number of spheres was significantly reduced in cells treated with the combination therapy compared with the control and monotherapy. Consistent with the phenomena, levels of the stem cell-associated markers Oct-4, CD44, CBX-7, and EZH2 were down-regulated after indicated treatments (Fig. 3E) . In addition, transwell assay was performed to explore the effect of combined drugs on the migration of HT-29 cells. As shown in Fig. 3B,D , the migration capacities of HT-29 cells were strongly decreased after dabrafenib and the combination treatments. Western blot analysis also revealed that the epithelial-mesenchymal transition (EMT)-associated proteins FAK, Snail, and Slug, were down-regulated in cells treated with dabrafenib alone or dabrafenib combined with cetuximab, whereas E-cadherin level was up-regulated (Fig. 3F) . Taken together, these results indicate that stem cell and migration capacities were reduced in CRC cells with BRAF(V600E) mutation when treated with the combination of dabrafenib and cetuximab.
Synergistic effect of dabrafenib with cetuximab possibly involves the PTEN/Src/c-Myc pathways
Numerous studies have shown the close relationship between NF-κB pathway and apoptosis, thus NF-κB-associated family proteins were firstly assessed by western blot analysis. As shown in Fig. 4A , no obvious changes were found in NF-κB2 proteins under indicated treatments. However, the expression level of p-IKKα/IKKβ was significantly down-regulated under dabrafenib and the combination treatments. These results suggest that dabrafenib with cetuximab may promote apoptosis by inactivating the NF-κB pathway through inhibiting p-IKKα/IKKβ.
Then we assessed the possible involvement of the PTEN/Src/c-Myc pathway in reducing the proliferation and viability of HT-29 cells treated with dabrafenib and cetuximab. As shown in Fig. 4B , Src phosphorylation was markedly reduced in cells treated with the dabrafenib and cetuximab compared with the control, whereas little difference was observed in cetuximab-treated cells. c-Myc was nearly absent in cells treated with the combination therapy and was noticeably reduced in cells treated with dabrafenib. In addition, Src kinase specific inhibitor AZD0530 was applied to evaluate the role of PTEN/Src/c-Myc pathway in the cytotoxic effect. After treated with 1 μM AZD0530 for 48 h, PTEN was up-regulated but c-Myc was down-regulated. Consistently, migration-associated proteins (FAK, E-cad, Snail, Slug) and stem cell-associated effectors (CD44) were also down-regulated after treatment with AZD0530. All the above results indicate that src may be the node modulator in the PTEN/Src/c-Myc pathway, which is probably partially involved in the cytotoxic effect.
Discussion
In the study, we found that when CRC cells with BRAF(V600E) mutation were exposed to a combination of dabrafenib and cetuximab, significantly increased cytotoxic effect was observed. While no synergistic effects were observed in Caco-2 (KRAS wt, BRAF wt) or HCT-116 (KRAS mt, BRAF wt) cells. The above phenomena indicate that the synergism might occur only in BRAF-mutant CRC cells. Therefore, our further in vitro studies mainly focused on the BRAF(V600E)-mutant HT-29 cells. The flow cytometry assay revealed that dabrafenib could cooperate with cetuximab to enhance apoptotic rates and cell cycle arrest, along with the consistent up/ down-regulation of cell cycle regulatory and apoptotic-associated proteins. Remarkably, to our knowledge, this is the first report showing that stem cell and migration capacities are strongly inhibited by the combination use of dabrafenib with cetuximab. Accumulating evidence has demonstrated that EMT process and CSC properties are two major factors that contribute to tumor relapse and drug resistance [23] . EMT process endows cells with more aggressive behaviors to gain distant metastatic abilities [24] . Cancer cells displaying stem cell features are thought to be located in a niche with mesenchymal cells to ensure their survival and regulate proliferation [25] . Cancer stem cells challenge the concept of a stochastic model of tumor generation, whereby each cell is assumed capable of tumorigenesis. Therefore, drug-resistant tumor cells are usually accompanied with EMT and CSC traits. Here, we found that the EMT-associated proteins and CSC sphere forming capacities, as well as CSC-associated proteins were decreased after combined treatment with dabrafenib and cetuximab, indicating that BRAF inhibitor could synergize with cetuximab to weaken stemness and metastatic capacities of CSC. In the past few years, major breakthroughs have been made by inhibiting the immune system for cancer treatment. Checkpoint blockade antibodies against PD-1 (Pembrolizumab, Nivolumab) and PD-L1 (Durvalumab, Atezolizumab) have achieved great clinical responses in advanced melanoma, NSCLC and several other tumors including colorectal cancer [26] [27] [28] . Recently, FDA has approved Pembrolizumab for adult patients with unresectable or metastatic solid tumors which are identified as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Thus, for those BRAF(V600E)-mutant colorectal cancer patients with MSI-H or dMMR, the effect of the combination of BRAF inhibitor with chemotherapy plus PD-1 antibodies may be tested in further investigation. In addition, inducing cancer cellular apoptosis have always been a strategy for cancer treatment, and several novel agents targeting the BCL-2 proteins are now in clinical trials [29] . As described above, the combination of dabrafenib with cetuximab promotes apoptosis by inactivation of NF-κB pathway through inhibiting p-IKKα/IKKβ. Previous literatures have shown p-IKKα/IKKβ can phosphorylate IkBα, a negative regulator of NF-κB, and release it from the interaction with NF-κB, thus induce the activation of NF-κB pathway [30] . In addition, dabrafenib can decrease the expression of BCL-2 (Fig. 2E) . All these results indicate that dabrafenib plus cetuximab and BCL-2 inhibitors might be another strategy for the treatment of patients with BRAF(V600E) mutation.
In conclusion, we showed that the combination use of dabrafenib with cetuximab could result in increased antitumor activity and decreased stem cell capacities in BRAF(V600E)-mutant CRC cells. In addition, a reduction in S-phase cells, an increased level of apoptosis, and a decreased activity of PTEN/Src/c-Myc were found in response to the combined use of BRAF and EGFR inhibitors in BRAF(V600E)-mutant CRC cells. This work further supports the need for combined therapies and personalized treatment in CRC patients. 
